Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Controlled, Double-Masked Study to Evaluate the Efficacy of IRX-101 in Reducing Post-Intravitreal Injection Pain and Corneal Epitheliopathy

NCT05747430 is registered in ClinicalTrials.gov with iRenix Medical, Inc. as lead sponsor.

NCT NCT05747430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05747430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Controlled, Double-Masked Study to Evaluate the Efficacy of IRX-101 in Reducing Post-Intravitreal Injection Pain and Corneal Epitheliopathy
Lead sponsor
iRenix Medical, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 22, 2023
Completion date
March 31, 2026
Enrollment
155 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

retinal disease